Abstracts
PO120
Selinexor-triplet therapy in patients with Central Nervous System Multiple Myeloma: A case series
Parisa Abedi1, Michael Davis2, Natalia Neparidze1
Introduction/Background/Significance: Multiple myeloma with CNS involvement is a rare but aggressive manifestation of the disease and is highly associated with poor outcome. Disease control is challenging as standard treatment of care has limited penetration into the CNS. Selinexor, an oral selective inhibitor of export (XPO1), can cross the blood-brain barrier, presenting potential for treating this patient population. However, clinical data to support its use are sparse. This case report addresses the unmet need for effective treatment by presenting results of selinexor-based triplet regimens in patients with relapsed/refractory CNS-MM.
